Mabpharm Limited (HK:2181) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mabpharm Limited has received approval from the Drug Regulatory Authority of Pakistan for its core product, CMAB008, an infliximab biosimilar used to treat several conditions including ulcerative colitis, rheumatoid arthritis, and psoriasis. This development marks a significant milestone for the company, offering a more cost-effective treatment option for patients. Investors might find this approval promising as it potentially enhances Mabpharm’s market reach and product portfolio.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.